Several studies, which have evaluated the effects of germline BRCA1/2 mutations on epithelial ovarian cancer prognosis, have shown that both PFS and OS were significantly improved in patients with BRCA mutations [31,32,33]. This evidence concerns the gene BRCA1 and ovarian carcinoma.